FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2185596403> ?p ?o ?g. }

• W2185596403 endingPage "e0144335" @default.
• W2185596403 startingPage "e0144335" @default.
• W2185596403 abstract "Patients with psoriasis are often affected by comorbidities, which largely influence treatment decisions. Here we performed conjoint analysis to assess the impact of comorbidities on preferences of patients with moderate-to-severe psoriasis for outcome (probability of 50% and 90% improvement, time until response, sustainability of success, probability of mild and severe adverse events (AE), probability of ACR 20 response) and process attributes (treatment location, frequency, duration and delivery method) of biologicals. The influence of comorbidities on Relative Importance Scores (RIS) was determined with analysis of variance and multivariate regression. Among the 200 participants completing the study, 22.5% suffered from psoriatic arthritis, 31.5% from arterial hypertension, 15% from cardiovascular disease (myocardial infarction, stroke, coronary artery disease, and/or arterial occlusive disease), 14.5% from diabetes, 11% from hyperlipidemia, 26% from chronic bronchitis or asthma and 12.5% from depression. Participants with psoriatic arthritis attached greater importance to ACR 20 response (RIS = 10.3 vs. 5.0, p<0.001; β = 0.278, p<0.001) and sustainability (RIS = 5.8 vs. 5.0, p = 0.032) but less value to time until response (RIS = 3.4 vs. 4.8, p = 0.045) than those without arthritis. Participants with arterial hypertension were particularly interested in a low risk of mild AE (RIS 9.7 vs. 12.1; p = 0.033) and a short treatment duration (RIS = 8.0 vs. 9.6, p = 0.002). Those with cardiovascular disease worried more about mild AE (RIS = 12.8 vs. 10, p = 0.027; β = 0.170, p = 0.027) and severe AE (RIS = 23.2 vs. 16.2, p = 0.001; β = 0.203, p = 0.007) but cared less about time until response (β = -0.189, p = 0.013), treatment location (β = -0.153, p = 0.049), frequency (β = -0.20, p = 0.008) and delivery method (β = -0.175, p = 0.023) than others. Patients’ concerns should be addressed in-depth when prescribing biologicals to comorbid patients, keeping in mind that TNF antagonists may favourably influence cardiovascular risk." @default.
• W2185596403 created "2016-06-24" @default.
• W2185596403 creator A5022415835 @default.
• W2185596403 creator A5040222818 @default.
• W2185596403 creator A5046125311 @default.
• W2185596403 creator A5055252208 @default.
• W2185596403 creator A5065324941 @default.
• W2185596403 creator A5068263359 @default.
• W2185596403 creator A5076386746 @default.
• W2185596403 date "2015-12-03" @default.
• W2185596403 modified "2023-09-26" @default.
• W2185596403 title "Patient Preferences for Biologicals in Psoriasis: Top Priority of Safety for Cardiovascular Patients" @default.
• W2185596403 cites W1500119734 @default.
• W2185596403 cites W1512005999 @default.
• W2185596403 cites W1661616496 @default.
• W2185596403 cites W1775194358 @default.
• W2185596403 cites W1873491332 @default.
• W2185596403 cites W1943930704 @default.
• W2185596403 cites W1966273028 @default.
• W2185596403 cites W1967077005 @default.
• W2185596403 cites W1967747990 @default.
• W2185596403 cites W1969097286 @default.
• W2185596403 cites W1977874369 @default.
• W2185596403 cites W1980883233 @default.
• W2185596403 cites W1994478140 @default.
• W2185596403 cites W1995586220 @default.
• W2185596403 cites W2005241673 @default.
• W2185596403 cites W2010277266 @default.
• W2185596403 cites W2012736637 @default.
• W2185596403 cites W2013300631 @default.
• W2185596403 cites W2014609423 @default.
• W2185596403 cites W2030019222 @default.
• W2185596403 cites W2030972148 @default.
• W2185596403 cites W2039862117 @default.
• W2185596403 cites W2044465471 @default.
• W2185596403 cites W2054785433 @default.
• W2185596403 cites W2056361036 @default.
• W2185596403 cites W2062864086 @default.
• W2185596403 cites W2063379728 @default.
• W2185596403 cites W2063867629 @default.
• W2185596403 cites W2064168005 @default.
• W2185596403 cites W2064890089 @default.
• W2185596403 cites W2066752983 @default.
• W2185596403 cites W2076953885 @default.
• W2185596403 cites W2081016717 @default.
• W2185596403 cites W2082622860 @default.
• W2185596403 cites W2082803782 @default.
• W2185596403 cites W2083180635 @default.
• W2185596403 cites W2085667526 @default.
• W2185596403 cites W2087273113 @default.
• W2185596403 cites W2087777607 @default.
• W2185596403 cites W2099706116 @default.
• W2185596403 cites W2104393910 @default.
• W2185596403 cites W2108984264 @default.
• W2185596403 cites W2112191043 @default.
• W2185596403 cites W2114677349 @default.
• W2185596403 cites W2116544705 @default.
• W2185596403 cites W2118322865 @default.
• W2185596403 cites W2131430597 @default.
• W2185596403 cites W2137606463 @default.
• W2185596403 cites W2145532966 @default.
• W2185596403 cites W2159513257 @default.
• W2185596403 cites W2170800858 @default.
• W2185596403 cites W2171624524 @default.
• W2185596403 cites W2467729800 @default.
• W2185596403 cites W3162959975 @default.
• W2185596403 cites W623659374 @default.
• W2185596403 cites W65358577 @default.
• W2185596403 doi "https://doi.org/10.1371/journal.pone.0144335" @default.
• W2185596403 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4669171" @default.
• W2185596403 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26633680" @default.
• W2185596403 hasPublicationYear "2015" @default.
• W2185596403 type Work @default.
• W2185596403 sameAs 2185596403 @default.
• W2185596403 citedByCount "18" @default.
• W2185596403 countsByYear W21855964032017 @default.
• W2185596403 countsByYear W21855964032018 @default.
• W2185596403 countsByYear W21855964032019 @default.
• W2185596403 countsByYear W21855964032020 @default.
• W2185596403 countsByYear W21855964032021 @default.
• W2185596403 countsByYear W21855964032022 @default.
• W2185596403 crossrefType "journal-article" @default.
• W2185596403 hasAuthorship W2185596403A5022415835 @default.
• W2185596403 hasAuthorship W2185596403A5040222818 @default.
• W2185596403 hasAuthorship W2185596403A5046125311 @default.
• W2185596403 hasAuthorship W2185596403A5055252208 @default.
• W2185596403 hasAuthorship W2185596403A5065324941 @default.
• W2185596403 hasAuthorship W2185596403A5068263359 @default.
• W2185596403 hasAuthorship W2185596403A5076386746 @default.
• W2185596403 hasBestOaLocation W21855964031 @default.
• W2185596403 hasConcept C126322002 @default.
• W2185596403 hasConcept C127413603 @default.
• W2185596403 hasConcept C134018914 @default.
• W2185596403 hasConcept C16005928 @default.
• W2185596403 hasConcept C164705383 @default.
• W2185596403 hasConcept C197934379 @default.
• W2185596403 hasConcept C2776260265 @default.
• W2185596403 hasConcept C2777575956 @default.

• next